LAUSR

FDE: fixed drug eruption CGRP: calcitonin gene-related peptide INTRODUCTION Fixed drug eruptions (FDEs) are defined by the recurrence of one or several skin lesions in a fixed location following exposure to an offending drug. Most FDEs occur following oral rather than parenteral drugs. However, FDEs following biologic therapy have been rarely reported. We present a case of a 48-year-old woman, whose clinical and pathologic findings were consistent with the diagnosis of FDE due to injections of galcanezumab-gnlm, amonoclonal antibody directed again calcitonin gene-related peptide (CGRP) which was approved in 2018 for the treatment of migraines. To our knowledge, this is the first reported case of FDE associated with galcanezumab-gnlm to date.